期刊文献+

Neutralization of Interleukin-9 Decreasing Mast Cells nfiltration in Experimental Autoimmune Encephalomyelitis 被引量:4

Neutralization of Interleukin-9 Decreasing Mast Cells nfiltration in Experimental Autoimmune Encephalomyelitis
原文传递
导出
摘要 Background: Th9 cells are a newly discovered CD4+ T helper cell subtype, characterized by high interleukin (IL)-9 secretion. Growing evidences suggest that Th9 cells are involved in the pathogenic mechanism of multiple sclerosis (MS). Mast cells are multifunctional innate imnmne cells, which are perhaps best known for their role as dominant effector cells in allergies and asthma. Several lines of evidence point to an important role lbr mast cells in MS and its animal models. Simultaneously, there is dynamic "'cross-talk" between Th9 and mast cells. The aim of the present study was to examine the IL-9-mast cell axis in experimental autoimmune encephalomyelitis (EAE) and deternaine its interaction alter neutralizing anti-lL-9 antibody treatment. Methods: Female C57BL/6 mice were randomly divided into three groups (#1 = 5 in each group): mice with myelin oligodendrocyte glycoprotein (MOG)-induced EAE (EAE group), EAE mice treated with anti-lL-9 antibody (anti-lL-9 Abs group), and EAE mice treated with IgG isotype control (lgG group). EAE clinical score was evaluated. Mast cells from central nervous system (CNS) were detected by flow cytometry. The production of chemokine recruiting mast cells in the CNS was explored by reverse transcription-polymerase chain reaction (RT-PCR). In mice with MOG-induced EAE, the expression of IL-9 receptor (IL-9R) complexes in CNS and spleen mast cells was also explored by RT-PCR, and then was repeating validated by immunocytochemistry. In vitro, spleen cells from EAE mice were cultured with anti-lL-9 antibody, and quantity of mast cells was counted by flow cytoinetry alter co-culture. Results: Compared with IgG group, IL-9 blockade delayed clinical disease onset and ameliorated EAE severity (t = -2.217, P- 0.031 ), accompany with mast cells infiltration decreases (day 5: t = -8.005, P 〈 0.001; day 15: t = -11.857, P 〈 0.001; day 20: t- 5.243, P = 0.001 ) in anti-lL-9 Abs group. The messenger RNA expressions of C-C motif chemokine ligand 5 (t = -5.932, P = 0.003) and vascular cell adhesion molecule-I (t = -4.029, P 0.004) were significantly decreased alter 1L-9 neutralization in anti-lL-9 Abs group, compared with lgG group. In MOG-induced EAE, the 1L-9R complexes were expressed in CNS and spleen mast cells. 1#7 vitro, splenocyles cultured with anti-lL-9 antibody showed significantly lower levels of mast cells in a dose-dependent manner, compared with splenocytes cultured with anti-mouse lgG (5 μg/ml: t = -0.894, P = 0.397; 10 p-g/ml: t = -3.348, P - 0.019:20 μg/ml: I - -7.639, P 〈 0.001 ).Conclusions: This study revealed that 1L-9 neutralization reduced mast cell infiltration in CNS and ameliorated EAE, which might be relate to the interaction between IL-9 and mast cells. Background: Th9 cells are a newly discovered CD4+ T helper cell subtype, characterized by high interleukin (IL)-9 secretion. Growing evidences suggest that Th9 cells are involved in the pathogenic mechanism of multiple sclerosis (MS). Mast cells are multifunctional innate imnmne cells, which are perhaps best known for their role as dominant effector cells in allergies and asthma. Several lines of evidence point to an important role lbr mast cells in MS and its animal models. Simultaneously, there is dynamic "'cross-talk" between Th9 and mast cells. The aim of the present study was to examine the IL-9-mast cell axis in experimental autoimmune encephalomyelitis (EAE) and deternaine its interaction alter neutralizing anti-lL-9 antibody treatment. Methods: Female C57BL/6 mice were randomly divided into three groups (#1 = 5 in each group): mice with myelin oligodendrocyte glycoprotein (MOG)-induced EAE (EAE group), EAE mice treated with anti-lL-9 antibody (anti-lL-9 Abs group), and EAE mice treated with IgG isotype control (lgG group). EAE clinical score was evaluated. Mast cells from central nervous system (CNS) were detected by flow cytometry. The production of chemokine recruiting mast cells in the CNS was explored by reverse transcription-polymerase chain reaction (RT-PCR). In mice with MOG-induced EAE, the expression of IL-9 receptor (IL-9R) complexes in CNS and spleen mast cells was also explored by RT-PCR, and then was repeating validated by immunocytochemistry. In vitro, spleen cells from EAE mice were cultured with anti-lL-9 antibody, and quantity of mast cells was counted by flow cytoinetry alter co-culture. Results: Compared with IgG group, IL-9 blockade delayed clinical disease onset and ameliorated EAE severity (t = -2.217, P- 0.031 ), accompany with mast cells infiltration decreases (day 5: t = -8.005, P 〈 0.001; day 15: t = -11.857, P 〈 0.001; day 20: t- 5.243, P = 0.001 ) in anti-lL-9 Abs group. The messenger RNA expressions of C-C motif chemokine ligand 5 (t = -5.932, P = 0.003) and vascular cell adhesion molecule-I (t = -4.029, P 0.004) were significantly decreased alter 1L-9 neutralization in anti-lL-9 Abs group, compared with lgG group. In MOG-induced EAE, the 1L-9R complexes were expressed in CNS and spleen mast cells. 1#7 vitro, splenocyles cultured with anti-lL-9 antibody showed significantly lower levels of mast cells in a dose-dependent manner, compared with splenocytes cultured with anti-mouse lgG (5 μg/ml: t = -0.894, P = 0.397; 10 p-g/ml: t = -3.348, P - 0.019:20 μg/ml: I - -7.639, P 〈 0.001 ).Conclusions: This study revealed that 1L-9 neutralization reduced mast cell infiltration in CNS and ameliorated EAE, which might be relate to the interaction between IL-9 and mast cells.
出处 《Chinese Medical Journal》 SCIE CAS CSCD 2017年第8期964-971,共8页 中华医学杂志(英文版)
关键词 Experimental Atltoimmune Encephalomyelitis lnterleukin-9 Mast Cell: Multiple Sclerosis TH9 Experimental Atltoimmune Encephalomyelitis lnterleukin-9 Mast Cell: Multiple Sclerosis Th9
  • 相关文献

参考文献2

二级参考文献21

  • 1Matas SL, Glehn FV, Femandes GB, Soares CA. Cerebrospinal fluid analysis in the context of CNS demyelinating diseases. Arq Neuropsiquiatr 2013;71:685-8. doi: 10.1590/0004-282x20130151.
  • 2Kira J. Neuromyelitis optica and opticospinal multiple sclerosis: Mechanisms and pathogenesis. Pathophysiology 2011 ;18:69-79. doi:10.1016/j .pathophys. 2010.04.008.
  • 3Wingerchuk DM, Hogancamp WF, O'Brien PC, Weinshenker BG. The clinical course of neuromyelitis optica (Devic's syndrome). Neurology 1999;53:1107-14. doi: 10.1212/WNL.53.5.1107.
  • 4Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, et aL Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011;69:292-302. doi: 10.1002/ana.22366,.
  • 5Wingerchuk DM, Banwelt B, Bennett JL, Cabre P, Carroll W, Chitnis I", et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 2015;85:177-89. doi: 10.1212/wnl.0000000000001729.
  • 6Disanto G, Ramagopalan SV. On the sex ratio of multiple sclerosis. Mult Scler 2013;19:3-4. doi: 10.1177/1352458512447594.
  • 7Pandit L, Asgari N, Apiwattanakul M, Palace J, Paul F, Leite MI, et al. Demographic and clinical features of neuromyelitis optica: A review. Mult Scler 2015;21:845-53. doi: 10.1177/1352458515572406.
  • 8Papais-Alvarenga RM, Vasconcelos CC, Carra A, de Castillo IS, Florentin S, Diaz de Bedoya FH, et al. Central nervous system idiopathic inflammatory demyelinating disorders in South Americans: A descriptive, multicenter, cross-sectional study. PLoS One 2015;10:e0127757. doi: 10.1371/journal.pone.0127757.
  • 9Asgari N. Epidemiological, clinical and immunological aspects of neuromyelitis optica (NMO). Dan Med J 2013;60:B4730.
  • 10Quek AM, McKeon A, Lennon VA, Mandrekar JN, lorio R, Jiao Y, et aL Effects of age and sex on aquaporin-4 autoimmunity. Arch Neurol 2012;69:1039-43. doi: 10.1001/archneurol.2012.249.

共引文献6

同被引文献8

引证文献4

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部